CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio

Sep 9, 2026

NEW HYDE PARK, N.Y.– CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo® (berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.1

“The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty platform in delivering high-touch, patient-centric care across rare, cancer, and orphan disease communities, and further positions us as a trusted partner for patients, providers, and manufacturers,” said Benito Fernandez, Chief Commercial Officer.

See the full prescribing information for Orladeyo.

Media Contact: Benito Fernandez, Chief Commercial Officer
[email protected] | 516.640.1332

References:
1Orladeyo® (berotralstat) [Package Insert]. Durham, NC. BioCryst Pharmaceuticals, Inc. 2025.